// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























959 Abstracts

Development and implementation of a non-invasive NGS-based diagnostic test for precision medicine in prostate cancer

Pan Du - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Dissecting the mechanism of AR-v7 nuclear translocation in prostate cancer

Seaho Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Kavya Pinto-Chengot - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Short-term outcomes of abiraterone in community settings

Grace L. Lu-Yao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

CB-7598

Alterations of TP53 mediate resistance to abiraterone in castration-resistant prostate cancer

Min Zou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Branched chain RNA in situ hybridization for the detection of androgen receptor splice variants within archival prostate cancer tissue

Philip J. Saylor - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC)

Jie-Fu Chen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Monitoring CHD1 during prostate cancer progression

Gunther Boysen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Genomic alterations in plasma cell-free DNA predict treatment response to abiraterone acetate and prednisone and survival in metastatic castration-resistant prostate cancer

Meijun Du - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer

Bryan Lemon - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Dynamic pro-survival signaling mediates resistance to androgen receptor targeted therapy in AR-v7 splice variant expressing prostate cancer models

Amanda Pilling - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

Heini M. Kallio - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression

Irfana Muqbil - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer

Mohammad Alyamani - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer

Sarah Q. To - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Analysis of circulating tumor DNA reveals genomic alterations in metastatic prostate cancer patients treated with abiraterone acetate plus prednisone or enzalutamide

Jelena Belic - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Inhibition of Protein Kinase N1 prevents control of AR over SRF action in advanced prostate cancer

Varadha Balaji Venkadarkrishnan - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Integrative and multiregional molecular analysis of localized, high grade prostate cancer treated with neoadjuvant androgen deprivation treatment

Stephanie A. Wankowicz - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Prognostic association of plasma cell free DNA (cfDNA) copy number variation based algorithmic score with survival in metastatic castration resistant prostate cancer (mCRPC)

Manish Kohli - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Magnetic iron oxide nanoparticles induce apoptosis and autophagic cell death in prostate cancer cells treated with docetaxel via ROS generation and NF-KB signaling

Kanako Kojima - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Copyright © 2026. QuantiNova All rights reserved